TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06611592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.35 mg/tid
Description: Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2: oral administration of a 0.18 mg/tid dose of pramipexole (0.25 mg salt).~Week 3 - Week 16 (end of treatment): oral administration of a 0.35 mg/tid dose of pramipexole (0.50 mg salt).
Study: NCT06617702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A text message alcohol intervention focused on cognitive, behavioral, and peer influences
Description: Each Thursday and Sunday ASPIRE will conduct brief text message communication aimed at modifying cognitive (e.g.desire to get drunk), behavioral (e.g.alcohol consumption), and peer influences (e.g.peer pressure and support).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A text message alcohol intervention focused on cognitive and behavioral influences
Description: Each Thursday and Sunday ASPIRE will conduct brief text message communication aimed at modifying cognitive (e.g. desire to get drunk) and behavioral (e.g. alcohol consumption) influences.
Study: NCT06617130

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Corn soy bean blended flour porridge plus indispensable amino acid
Description: Protocol treatment will start within two weeks of enrollment to the study. Following the baseline study assessments, each participant will receive corn-soy bean blended flour porridge supplemented with IAAs (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) dosed at 12g/d and providing 1.5 times the estimated average requirement (EAR) for a healthy child (Intervention group). The porridge will provide 30% daily energy requirement. The study foods will be taken once daily by the child with at least three observed feeding sessions per week over the 4 weeks of the study to assess compliance.~Children in the control arm will receive corn-soy blended flour porridge without added amino acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn soy bean blended flour porridge plus indispensable amino acid
Description: Protocol treatment will start within two weeks of enrollment to the study. Following the baseline study assessments, each participant will receive corn-soy bean blended flour porridge supplemented with IAAs (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) dosed at 12g/d and providing 1.5 times the estimated average requirement (EAR) for a healthy child (Intervention group). The porridge will provide 30% daily energy requirement. The study foods will be taken once daily by the child with at least three observed feeding sessions per week over the 4 weeks of the study to assess compliance.~Children in the control arm will receive corn-soy blended flour porridge without added amino acids.
Study: NCT06616909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP GAME
Description: ,Using board games as an activity intervention, a tool for discussion between elderly people with lung cancer and potential agents

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: acp manual
Description: acp manual
Study: NCT06616922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD03/2016 eye drops
Description: 1 drop, 4 times a day (approximately every 4 hours while awake) for 5 days starting from Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 0.5% eye drops solution (Oftaquix®)
Description: 1 drop, 8 times a day (approximately every 2 hours while awake) on Days 1 and 2, and 1 drop, 4 times a day (approximately every 4 hours while awake) on Days 3 through 5.
Study: NCT06616935

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group one, community activities.
Description: Intervention group one: participants will have a list of free activities in the community provided by third sector organisations to choose from. Participants will be referred to their chosen activities and expected to attend for six months.~Intervention group two: Participants will attend weekly online exercises and activities led by the researcher.

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention group two
Description: Online exercises and activities
Study: NCT06616480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BenQ Materials DSFNC1 soft hydrophilic contact lenses
Description: Test lenses were to be worn for approximately 90 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visco SiHy Color soft hydrophilic contact lenses
Description: Control lenses were to be worn for approximately 90 days
Study: NCT04901078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KNX100
Description: KNX100 will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KNX100
Description: KNX100 will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.
Study: NCT04832282

Intervention type: DEVICE
Group type: OTHER
Intervention: Napoleon
Description: The Micro-Tech Endoscopic Measurement Device named Napoleon is a small catheter with a 30mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA. The device was originally intended to measure polyps. However, it is used off-label in this study and is considered investigational.

Intervention type: OTHER
Group type: OTHER
Intervention: Visual estimation
Description: For each case, endoscopists will first visually estimate the diameter of the GJA by comparing its size to the upper endoscope.
Study: NCT06216860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Description: In Laughter Yoga Practice; each session will last approximately 30 - 45 minutes and will consist of four parts. These parts are: warm-up exercises, deep breathing exercises, childlike games and laughter exercises.
Study: NCT06502652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hippotherapy
Description: A hippotherapy simulator is a horse riding simulator exercise machine, mimicking a horse's gait and recreating the horseback riding experience within the safety of a therapy clinic. Child with down syndrome will be seated on the stimulator for 10-15 minutes every session. The patient's pelvis moves softly, rhythmically, and repetitively when riding this action is comparable to what the human pelvis does when walking normally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balance training
Description: The therapist modified the railing height to suit each child, ensuring the children were standing erect on the treadmill. Treadmill training completed under three conditions in 1-min training cycles. For 15 s of each minute the child could hold on to the railings with both hands, for the next 15 s with one hand, and finally with no hands on the handrails for 30 s. Each child repeated this procedure 20 Times and cool down for 5 minutes
Study: NCT06402682

Intervention type: PROCEDURE
Intervention: Right approach
Description: Right approach of the management of esophageal atresia with a right aortic arch

Intervention type: PROCEDURE
Intervention: Left approach
Description: Left approach of the management of esophageal atresia with a right aortic arch
Study: NCT06227117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Injection （18 weeks）
Description: 2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Injection （18 weeks）
Description: 2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab （18weeks）
Description: 3.0 mg/kg, intravenous infusion, D1, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab （18weeks）
Description: 3.0 mg/kg, intravenous infusion, D1, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 3 Q2W or AUC1.5 QW intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Injection （12 weeks）
Description: 2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential Epirubicin
Description: According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential CTX
Description: According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab （12weeks）
Description: 3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed.
Study: NCT06313060

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coca-cola
Description: 200 ml of Coca-Cola will be administered and must be ingested within a maximum of 10 minutes
Study: NCT05596292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality glasses
Description: The immersive virtual reality glasses support a smartphone device, allowing videos to be used with 360º rotation and earpods headphones with bluetooth for sound. Video options will be offered to participants according to the exercise performed, ie: a cycling video for activities with a cycle ergometer; video with people walking for ambulation; and videos of the patient's choice, such as forest, beach or city scenarios, for other moments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: early mobilization protocol
Description: Three days of an early mobilization protocol. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early mobilization protocol
Description: Three days of an early mobilization protocol. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation.
Study: NCT06297655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human activated coagulation factor VIII for injection
Description: Recombinant human coagulation factor VIII for injection is a recombinant DNA product with functional characteristics comparable to endogenous factor VIII.
Study: NCT05099523

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: taking arterial blood sample through the injector
Description: taking blood samples from patients applied with different oxygen concentrations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: taking arterial blood sample through the injector
Description: taking blood samples from patients applied with different oxygen concentrations
Study: NCT05422352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnosine
Description: Patients who will receive carnosine supplementation 500mg capsules (Now foods) in combination with Vitamin B complex (B1+B6+B12, 150 mg+100 mg+1 mg, respectively, Neurovit, European Egyptian Pharm. Ind., Egypt), two tablets per day
Study: NCT06155773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Highly viscous glass ionomer (cervical margin relocation)
Description: different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low shrinkage Flowable Composite (cervical margin relocation)
Description: different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resin Modified Glass Ionomer (cervical margin relocation)
Description: different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bioactive Ionic Resin (cervical margin relocation)
Description: different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
Study: NCT05585931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 10mg
Description: Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 10mg
Description: Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H Placebo
Description: Subjects were given Placebo with 240 mL warm water under fasting condition.
Study: NCT05580055

Intervention type: DIAGNOSTIC_TEST
Intervention: Affinity
Description: Blood Analyser

Intervention type: DIAGNOSTIC_TEST
Intervention: Affinity
Description: Blood Analyser
Study: NCT06296433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR rehabilitation
Description: VR software application containing education, exergames, therapeutic exercises and relaxation sections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VR video application
Description: VR software application that plays 2D nature videos
Study: NCT06187844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inguinal exploration
Description: Inguinal exploration will be done for all the included patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: All patients will have abdominal laparoscopy first to assess the location of the impalpable testis, the inguinal canal and the cord structures.
Study: NCT06519552

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JWK008 Single intravenous infusion administration
Description: Six participants with MPS I will be enrolled in the study. The participantss will be divided into two different dose groups, and a 3+3 dose escalation design is used. The low dose is 5.0×10\^12vg/kg, and the high dose is 2.0×10\^13vg/kg. Only one intravenous infusion of JWK008 will be administered to each participant.
Study: NCT06065527

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Map Our Life
Description: The intervention takes participants through the process of planning using the Preparation for Future Care Model stages: care expectation, awareness, information gathering, decision making, and concrete planning. The intervention has 8 modules: (1) Letter of Intent for Your Loved One, (2) Caregiver Support and Well-Being, (3) Medical Decision Making for Your Loved One, (4) Daily Routines and Medical Management, (5) Medicaid Waiver for Your Loved One, (6) Financial Planning for Your Loved One, (7) Emergency Planning for Your Loved One, and (8) Managing Jobs, Day Programs, and Transportation. Map Our Life takes users - the caregiver alongside the individual with intellectual disability - through the stages of planning in each of the 8 modules until a concrete care plan is developed. The last component of the intervention is that this Care Plan is subsequently saved and shared with others such as care managers, clinicians, friends or family members.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: The control group will have access to a CDC Website, CDC Healthy Living with a Disability.
Study: NCT05781971

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high protein
Description: Patients in high-protein group will be given a target protein amount of 2.0 g/kg/d. Standard enteral nutrition is the first choice,the remaining target value will be met by intravenous amino acid infusion.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high protein
Description: Patients in high-protein group will be given a target protein amount of 2.0 g/kg/d. Standard enteral nutrition is the first choice,the remaining target value will be met by intravenous amino acid infusion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: In this trial, the investigator will provide early rehabilitation treatment such as respiratory training, bicycle training, and medium frequency electrical stimulation to patients.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: rehabilitation
Description: In this trial, the investigator will provide early rehabilitation treatment such as respiratory training, bicycle training, and medium frequency electrical stimulation to patients.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: standard protein
Description: The investigator set a protein target of 1.2 g/Kg/d for the standard protein group, which will be supplied enterally or parenterally.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: standard protein
Description: The investigator set a protein target of 1.2 g/Kg/d for the standard protein group, which will be supplied enterally or parenterally.
Study: NCT05096871

Intervention type: GENETIC
Intervention: Genotyping by Real Time PCR
Description: 3 mL of blood will be withdrawn by venipuncture in EDTA tube. DNA extraction will be done after centrifugation and used for genotyping assay of ( BDNF ) gene with the Real- time polymerase chain reaction.~BDNF level in serum will also be analyzed by Sandwich enzyme linked immunosorbant assay kit ( ELISA).
Study: NCT05585931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H Placebo
Description: Subjects were given Placebo with 240 mL warm water under fasting condition.
Study: NCT05237258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialty Palliative Care
Description: Participants assigned to specialty palliative care will be cared for by both oncology and palliative care clinicians during their hospital stays for AML.
Study: NCT05842304

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active cTBS
Description: Each patient will receive three 600-pulse cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham cTBS
Description: Each patient will receive three 600-pulse sham cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
Study: NCT06696638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EIT-guided Phigh settings during APRV
Description: The Phigh level selected for the patients in the Intervention group was the intercept point of cumulated collapse and overdistension percentage curves, providing the best compromise between collapsed and overdistended lung.
Study: NCT05237258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Palliative Care
Description: Participants assigned primary palliative care will be cared for by oncology clinicians who have been trained in palliative care during the hospital stays for AML.
Study: NCT06121310

Intervention type: OTHER
Intervention: Survey
Description: Non interventional. Pediatric anesthesia satisfaction scale validity and reliability is going to investigate by survey analyses
Study: NCT06287502

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-hydroxy β-methylbutyrate (HMB)
Description: Ensure NutriVigor, a nutritional supplement, was provided to subjects according to the manufacturer's recommendation of two servings per day. Each serving consists of 54.1g of powder which provides \~231kcal, 8.61g protein, 1.21 g β-hydroxy β-methylbutyrate, 130 IU vitamin D and 0.29 g omega-3 fatty acid.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance, aerobic, flexibility and balance exercise training
Description: The exercise intervention consists of 75-minutes sessions delivered by physiotherapists at the Integrated Rehabilitation Day Centre (IRDC) in Kowloon Hospital, twice per week for 12 weeks with a total of 24 supervised sessions. Each exercise session consists of 5 minutes of warm up, 30 minutes of resistance training, 20 minutes of aerobic training, 15 minutes of balance or neuromuscular exercises and 5 minutes of cool down.
Study: NCT05524441

Intervention type: OTHER
Intervention: Circadian Disruption - Quasi-Experimental
Description: 2 conditions: comparing trips with circadian disruption to trips without circadian disruption

Intervention type: OTHER
Intervention: Circadian Disruption - Quasi-Experimental
Description: 2 conditions: comparing trips with circadian disruption to trips without circadian disruption

Intervention type: OTHER
Intervention: Circadian Disruption - Quasi-Experimental
Description: 2 conditions: comparing trips with circadian disruption to trips without circadian disruption

Intervention type: OTHER
Intervention: Circadian Disruption - Quasi-Experimental
Description: 2 conditions: comparing trips with circadian disruption to trips without circadian disruption
Study: NCT05544422

Intervention type: OTHER
Group type: OTHER
Intervention: The Timed Up & Go Test and 30second Chair-Stand Test'
Description: Evaluation of the participants will be carried out in the following order; 1) traditional assessment, 2) tele-assessment, 3) post-test. In the final test, only tele-assessment of the tests will be made.~During testing sessions, the results of each TUG and 30s-CST trial will be recorded on a standard test paper. TUG and 30s-CST will be tested in two different ways, traditional and tele, as 2 sessions every other day. Participants will rest for five to ten minutes between trials and an hour between sessions. During the one-hour rest between two test sessions, participants will rest in a chair, wheelchair or bed. Assessors will not know the TUG and 30s-CST results scored by each other.